stroke_antithromboticrx
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| stroke_antithromboticrx [2026/08/31 10:33] – [balance the stroke prevention benefits with risk of major bleeding] gary1 | stroke_antithromboticrx [2026/08/31 10:33] (current) – [new AMI and non-valvular AF] gary1 | ||
|---|---|---|---|
| Line 51: | Line 51: | ||
| *for patients who have an AMI and are in AF: | *for patients who have an AMI and are in AF: | ||
| * patients who have recently had a myocardial infarction receive antiplatelet therapy, in particular the combination of aspirin and a potent P2Y12 inhibitor, to reduce their risk of another ischemic event | * patients who have recently had a myocardial infarction receive antiplatelet therapy, in particular the combination of aspirin and a potent P2Y12 inhibitor, to reduce their risk of another ischemic event | ||
| - | * HOWEVER, avoid using prasugrel or ticagrelor with a DOAC (the experimental arm in this study) as the 2026 EPIDAURUS trial comparing this with DOAC plus clopidogrel with in-hospital aspirin control group for a 1 month duration post AMI was terminated early as there was no evidence of benefit of the experimental arm and a 3.5x risk of significant bleeding(([[https:// | + | * HOWEVER, |
stroke_antithromboticrx.txt · Last modified: 2026/08/31 10:33 by gary1